Register
Lusutrombopag approved by EMA for thrombocytopenia in adults with liver |
Clinical News
eMediNexus Coverage from: 
Lusutrombopag approved by EMA for thrombocytopenia in adults with liver

0 Read Comments                

The European Medicine Agencys (EMAs) Committee for Medicinal Products for Human Use has approved the thrombopoietin receptor agonist Lusutrombopag Shionogi for the treatment of severe thrombocytopenia in adults with chronic liver disease who are to undergo an invasive procedure.

It reduces the need for platelet transfusions before primary invasive procedures and can be used for rescue therapy in the event of bleeding during the 7 days after such procedures.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now